Role of selective serotonin reuptake inhibitors in psychiatric disorders: A comprehensive review

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 1, 2003, Pages 85-102

  Vaswani, Meera ^a   Linda, Farzana Kadar ^a   Ramesh, Subramanyam ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anxiety disorders; Citalopram; Depression; Eating disorders; Fluovoxamine; Fluoxetine; Obsessive compulsive disorder; Paroxetine; Pharmacokinetics; Pharmacology; Serotonin; Sertraline; SSRIs

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 2D6; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORFLUOXETINE; PAROXETINE; PHENELZINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZIMELDINE;

AGING; ANOREXIA; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; BEHAVIOR THERAPY; BLEEDING; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EATING DISORDER; ENZYME ACTIVITY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; IMPULSE CONTROL DISORDER; INSOMNIA; LACTATION; MENTAL DISEASE; META ANALYSIS; MOTOR DYSFUNCTION; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PREGNANCY; PREMENSTRUAL SYNDROME; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA; SEDATION; SEROTONIN UPTAKE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SUICIDAL BEHAVIOR; TREATMENT OUTCOME; TREMOR; VERTIGO; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANXIETY DISORDERS; CHILD; DEPRESSIVE DISORDER; EATING DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME; SUICIDE, ATTEMPTED;

EID: 0037302791     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00338-X     Document Type: Review

References (197)

1. Agras W.S. Pharmacotherapy of bulimia nervosa and binge eating disorder: longer-term outcomes. Psychopharmacol. Bull. 33(3):1997;433-436.
2. Amsterdam J.D., Fawcett J., Quitkin F.M., Reimherr F.W., Rosenbaum J.F., Michelson D., Hornig R.M., Beasley C.M. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am. J. Psychiatry. 154:1997;963-969.
3. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 58:2000;19-36.
4. Arfken C.L., Wilson J.G., Aronson S.M. Retrospective review of selective serotonin reuptake inhibitors and falling in older nursing home residents. Int. Psychogeriatr. 13(1):2001;85-91.
5. Ashton H. The treatment of benzodiazepine dependence. Addiction. 89:1994;1535-1541.
6. Baldwin D.S. Clinical experience with paroxetine in social anxiety disorder. Int. Clin. Psychopharmacol. 15(Suppl. 1):2000;S19-S24.
7. Baldwin D.S., Hawley C.J., Abed R.T., Maragakis B.P., Cox J., Buckingham S.A., Pover G.H., Ascher A. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J. Clin. Psychiatry. 57(Suppl. 2):1996;46-52.
8. Ballenger J.C., Davidson J.R., Lecrubier Y., Nutt D.J., Bobes J., Beidel D.C., Ono Y., Westenberg H.G. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry. 59(Suppl. 17):1998;54-60.
9. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 31:1996;444-469.
10. Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int. Clin. Psychopharmacol. 11(Suppl. 1):1996;5-11.
11. Baumann P. Care of Depression in the elderly: comparative pharmacokinetics of SSRIs. Int. Clin. Pharmacol. 13(Suppl. 5):1998;S35-S43.
12. Bauman P., Larsen F. The pharmacokinetics of citalopram. Rev. Contemp. Pharmacother. 6:1995;287-295.
13. Beasley C.M. Jr., Bosomworth J.C., Wernicke J.F. Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacology. 26:1990;18-24.
14. Beasley B.M., Dornseif B.E., Bosomworth J.C., Sayler M.E., Rampey A.H., Heilgenstein J.H., Thompson V.L., Murphy D.J., Masica D.N. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br. Med. J. 303:1991;685-692.
15. Bender S., Eap C.B. Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch. Gen. Psychiatry. 55:1998;1048-1050.
16. Benfield P., Heel R.C., Lewis S.P. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 32:1986;481-508.
17. Black D.W., Wesner R., Bowers W., Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch. Gen. Psychiatry. 50(1):1993;44-55.
18. Bourin M., Chue P., Guillon Y. Paroxetine: a review. CNS Drugs Rev. (1):2001;25-47.
19. Bowers W.A., Andersen A.E. In-patient treatment of anorexia nervosa: review and recommendations. Harv. Rev. Psychiatry. 2(4):1994;193-203.
20. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int. Clin. Psychopharmacol. 10(1):1995;45-49.
21. Brosen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther. Drug Monit. 18:1996;393-396.
22. Brosen K., Skjelbo E., Rasmussen B.B., Poulsen H.E., Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45(6):1993;1211-1214.
23. Burke M.J., Preskorn S.H. Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice. Clin. Pharmacokinet. 37(2):1999;147-165.
24. Carlsson A. The discovery of the SSRIs: a milestone in neuropsychopharmacology and rational drug design. Stanford S.C. Selective Serotonin Reuptake Inhibitors (SSRIs). Past, Present and Future. 1999;1-7 RG Landes, Austin, TX, USA.
25. Carlsson A., Lindqvist M. Central and peripheral membrane pump blockade by some addictive analgesics and antihistaminics. J. Pharm. Phramacol. 21:1969;460-464.
26. Carrillo J.A., Dahl M.L., Svensson J.O., Alm C., Rodriguez I., Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin. Pharmacol. Ther. 60(2):1996;183-190.
27. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. 3, 335(14):1996;1010-1015.
28. Charney D.S., Krystal J.H., Delgado P.L., Henninger G.R. Serotonin specific drugs for anxiety and depressive disorders. Ann. Rev. Med. 41:1990;437-446.
29. Claassen V. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br. J. Clin. Pharmacol. 15:1983;349S-355S.
30. Clerc G.E., Ruimy P., Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in atients hospitalized for major depression and melancholia: the Venlafaxine French in patient's study group. Int. Clin. Psychopharmacol. 9:1994;139-143.
31. Cole M.G., Elie L.M., McCusker J., Bellavance F., Mansour A. Feasibility and effectiveness of treatments for post-stroke depression in elderly in-patients: systematic review. J. Geriatr. Psychiatry Neurol. 14(1):2001;37-41.
32. Crane G.E. Iproniazid (marsilid) phosphate: a therapeutic agent for mental disorders and debilitating disease. Psychiatry Res. Rep. 8:1957;142-152.
33. Crew H.W., Lennard M.S., Tucker G.T., Woods F.R., Haddock R.E. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 34(3):1992;262-265.
34. Cusack B., Nelson A., Ruhelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology. 114:1994;559-565.
35. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 90:1986;131-138.
36. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 18:1990;289-299.
37. Davidson J.R., Malik M.L., Sutherland S.N. Response characteristics to antidepressants and placebo in post-traumatic stress disorder. Int. Clin. Psychopharmacol. 12(6):1997;291-296.
38. Davidson J.R., Weisler R.H., Malik M., Tupler L.A. Fluvoxamine in civilians with posttraumatic stress disorder. J. Clin. Psychopharmacol. 18(1):1998;93-95.
39. Davis L.L., Yonkers K.A., Trivedi M., Kramer G.L., Petty F. The mechanism of action of SSRIs: a new hypothesis. Stanford S.C. Selective Serotonin Reuptake Inhibitors (SSRIs): Past, Present and Future. 1999;181-182 RG Landes, Austin, TX, USA.
40. De Boer M., Op den Velde W., Falger P.J., Hovens J.E., De Groen J.H., Van Duijn H. Fluvoxamine treatment for chronic PTSD: a pilot study. Psychother. Psychosom. 57(4):1992;158-163.
41. Debus J.R., Rush A.J., Himel C., Tyler D., Polatin P., Weissenburger J. Fluoxetine versus trazodone in the treatment of outpatients with major depression. J. Clin. Psychiatry. 49:1988;422-426.
42. de Jonghe F., Swinkels J. Selective serotonin reuptake inhibitors: relevance of differences in their pharmacological and clinical profiles. CNS Drugs. 7:1997;452-467.
43. Delgado P.L., Charney D.S., Price L.H., Landis H., Heninger G.R. Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. Life Sci. 45(24):1989;2323-2332.
44. DeVane C.L. Pharmacokinetics of the newer antidepressants: clinical relevance. Am. J. Med. 97(6A):1994;13S-23S.
45. DeVries M.H., Raghoebar M., Mathlener I.S., Van-Harten J. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther. Drug Monit. 14(6):1992;493-498.
46. DeVries M.H., VanHarten J., VanBemmel P., Raghoebar M. Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm. Drug Dispos. 14(4):1993;291-296.
47. Dierick M., Ravizza L., Realini R., Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 20:1996;57-71.
48. Dubovsky S.L., Thomas M. Beyond specificity: effects of serotonin and serotonergic treatments on psycho-biological dysfunction. J. Psychosom. Res. 39(4):1995;429-444.
49. Edwards G., Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs. 57(4):1999;507-533.
50. Elks M.L. Open trial of fluoxetine therapy for premenstrual syndrome. South. Med. J. 86:1993;503-507.
51. Emslie G., Judge R. Tricyclic antidepressants and selective serotonin reuptake inhibitors: use during pregnancy, in children/adolescents and in the elderly. Acta Psychiatr. Scand., Suppl. 403:2000;26-34.
52. Etain B., Bonnet-Perrin E. Value of fluoxetine in obsessive compulsive disorder in adult: review. Encephale. 27(3):2001;280-289.
53. Fagius J., Osterman P.O., Siden A., Wiholm B.E. Guillain-Barre syndrome following zimeldine treatment. J. Neurol. Neurosurg. Psychiatry. 48:1985;65-69.
54. Fava M., Rosenbaum J.F., Pava J.K., McCarthy M.K., Steingard R.J., Bouffides E. Anger attacks in unipolar depression: Part 1. Clinical co-relates and response to fluoxetine treatment. Am. J. Psychiatry. 150:1993;1158-1163.
55. Feiger A., Kiev A., Shrivastava R.K., Wisselink P.G., Wilcox C.S. Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction. J. Clin. Psychiatry. 57(Suppl. 2):1996;53-62.
56. Ferguson C.P., LaVia M.C., Crossan P.J., Kaye W.H. Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int. J. Eat. Disord. 25(1):1999;11-17.
57. Figgitt D.P., McClellan K.J. Fluvoxamine: an updated review of its use in the management of adults with anxiety disorders. Drugs. 60(4):2000;925-954.
58. Fjordside L., Jeppesen U., Eap C.B., Powell K., Baumann P., Brosen K. The stereo-selective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics. 9(1):1999;55-60.
59. Fleishaker J.C., Hulst L.K. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur. J. Clin. Pharmacol. 46(1):1994;35-39.
60. Frank G.K., Kaye W.H., Marcus M.D. Sertraline in underweight, binge eating/purging-type eating disorders: five case reports. Int. J. Eat. Disord. 29(4):2001;495-498.
61. Fuller R.W. Pharmacologic modification of serotonergic function: drugs for the study and treatment of psychiatric and other disorders. J. Clin. Psychiatry. 47:1986;4-8. (Suppl.).
62. Fuller R.W., Wong D.T., Robertson D.W. Fluoxetine: a selective inhibitor of serotonin uptake. Med. Res. Rev. 11(1):1991;17-34.
63. Geddes J.R., Freemantle N., Mason J., Eccles M.P., Boynton J. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst. Rev. 2:2000;. (CD001851).
64. George M.S., Lydiard R.B. Speed of onset of action of the newer antidepressants - fluoxetine and bupropion. Int. Clin. Psychopharmacol. 6:1991;209-217.
65. Gerber P., Lynd L.D. Selective serotonin reuptake inhibitor induced movement disorders. J. Clin. Psychiatry. 32:1998;692-698.
66. Gonzalez-Heydrich J., Peroutka S.J. Serotonin receptor and reuptake sites: pharmacologic significance. J. Clin. Psychiatry. 51:1990;5-12. (Suppl.).
67. Goodwin G.M. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J. Clin. Psychiatry. 57(Suppl. 4):1996;9-13.
68. Graeff F.G. Serotonergic systems. Psychiatr. Clin. North Am. 20:1997;723-739.
69. Gram L.F. Fluoxetine. N. Engl. J. Med. 331:1994;1354-1361.
70. Greenblatt D.J., von Moltke L.L., Schmider J., Harmatz J.S., Shader R.I. Inhibition of human cytochrome P450-3A: isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J. Clin. Pharmacol. 36:1996;792-798.
71. Gupta R.N., Dziurdzy S.A. Therapeutic monitoring of sertraline. Clin. Chem. 40:1994;498-499.
72. Gupta S., Masand P.S., Rangwani S. Selective serotonin reuptake inhibitors in pregnancy and lactation. Obstet. Gynecol. Surv. 53:1998;733-736.
73. Hamelin B.A., Turgeon J., Vallee F., Belanger P.M., Paquet F., LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin. Pharmacol. Ther. 60(5):1996;512-521.
74. Haria M., Fitton A., McTavish D. Trazodone. Drugs Aging. 4:1994;331-355.
75. Hartter S., Wetzel H., Hammes E., Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology (Berlin). 110:1993;302-308.
76. Hellerstein D.J., Yanowitch P., Rosenthal J., Hemlock C., Kasch K., Samstag L.W., Winston A. Long-term treatment of double depression: a preliminary study with serotonergic antidepressants. Prog. Neuropsychopharmacol. Biol. 18:1994;139-147.
77. Hemeryck A., Belpaire F.M. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr. Drug Metab. 3(1):2002;13-37.
78. Herrmann N. Use of SSRIs in the elderly: obvious benefits but unappreciated risks. Can. J. Clin. Pharmacol. 7(2):2000;91-95.
79. Hiemke C., Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. 85(1):2000;11-28.
80. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46(2):1994;157-203.
81. Hughes J., Lunn B., O'Brien J. SSRIs and patient groups with specific treatment problems. Stanford S.C. Selective Serotonin Reuptake Inhibitors (SSRIs). Past, Present and Future. 1999;47-64 RG Landes, Austin, TX, USA.
82. Jacobsen F.M. Fluoxetine induced sexual dysfunction and an open trial of yohinbine. J. Clin. Psychiatry. 53:1992;119-122.
83. Jeppesen U., Gram L.F., Vistisen K., Loft S., Paulsen H.E., Brosen K. Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 51:1996;73-78.
84. Jimerson D.C., Herzog D.B., Brotman A.W. Pharmacologic approaches in the treatment of eating disorders. Harv. Rev. Psychiatry. 1(2):1993;82-93.
85. Karasu T.B., Gelenberg A., Merriam A., Wang P. Practice guidelines for the treatment of patients with major depressive disorder. APA Guidelines for the Treatment of Psychiatric Disorders. 2000;461 APA, Washington, DC.
86. Kasper S., Dotsch M., Kick H., Vieira A., Moller H.J. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur. Neuropsychopharmacol. 3(1):1993;13-21.
87. Kastelic E.A., Labellarte M.J., Riddle M.A. Selective serotonin reuptake inhibitors for children and adolescents. Curr. Psychiatry Rev. 2(2):2000;117-123.
88. Kaye C.M., Haddock R.E., Langley P.F., Mellows G., Tasker T.C., Zussman B.D., Greb W.H. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr. Scand. 80(Suppl. 350):1989;60-75.
89. Kaye W., Gendall K., Strober M. Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biol. Psychiatry. 44(9):1998;825-838.
90. Kelsey J.E., Nemeroff C.B. Selective serotonin reuptake inhibitors. Sadock B.J., Sadock V.A. Comprehensive Textbook of Psychiatry. vol. 2:2000;2432-2444 Lippincott Williams and Wilkins, USA.
91. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H.U., Kendler K.S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry. 51(1):1994;8-19.
92. Kirby D., Ames D. Hyponatraemia and selective serotonin reuptake inhibitors in elderly patients. Int. J. Geriatr. Psychiatry. 16(5):2001;484-493.
93. Kobayashi K., Yamamoto T., Chiba K., Tani M., Ishizaki T., Kuroiwa Y. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br. J. Clin. Pharmacol. 40(5):1995;481-485.
94. Kobayashi K., Chiba K., Yagi T., Shimada N., Taniguchi T., Horie T., Tani M., Yamamoto T., Shizaki T., Kuroiwa Y. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J. Pharmacol. Exp. Ther. 280:1997;927-933.
95. Koponen H., Lepola U., Leinonen E., Jokinen R., Penttinen J., Turtonen J. Citalopram in the treatment of obsessive compulsive disorder: an open pilot study. Acta Psychiatr. Scand. 96:1997;343-346.
96. Koran L.M., Caine J.W., Dominguez R.A., Rush R.J., Thieman S. Are fluoxetine levels related to outcome in obsessive compulsive disorder. Am. J. Psychiatry. 153(11):1996;1450-1454.
97. Kuhn R. The treatment of depressive states with G-22355 (imipramine hydrochloride). Am. J. Psychiatry. 115:1958;459-464.
98. Kuhs H., Schlake H.P., Rolf L.H., Rudolf G.A. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline. Acta Psychiatr. Scand. 85(5):1992;364-369.
99. Kulin N.A., Pastuszak A., Sage S.A. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. J. Am. Med. Assoc. 279:1998;609-616.
100. Lane R.M. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. 11(Suppl. 5):1996;31-61.
101. Leinonen E., Lepola U., Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry. 29(4):1996;156-158.
102. Leo R.J. Movement disorders associated with the selective serotonin reuptake inhibitors. J. Clin. Psychiatry. 57:1996;449-454.
103. Levine M., Bellward G.D. Effect of cimetidine on hepatic cytochrome P450: evidence for formation of a metabolite-intermediate complex. Drug Metab. Dispos. 23:1995;1407-1411.
104. Lin J.H., Lu A.Y.H. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35(5):1998;361-390.
105. Lonnqvist J., Sintonen H., Syvalahti E. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr. Scand. 89:1994;363-369.
106. Lundmark J., Thomsen I.S., Fjord-Larsen T., Manniche P.M., Mengel H., Moller-Nielsen E.M., Pauser H., Walinder J. Paroxetine: pharmacokinetic and antidepressant effects in the elderly. Acta Psychiatr. Scand. 80(Suppl. 350):1989;76-80.
107. Macqueen G., Born L., Steiner M. The selective serotonin reuptake inhibitors sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 7(1):2001;1-24.
108. Marcus E.R., Bradley S.S. Combination of psycotherapy and psychopharmacotherapy with treatment resistant inpatients with dual diagnoses. Psychiatr. Clin. North Am. 13:1990;209-214.
109. Marshall R.D., Schneier F.R., Fallon B.A., Knight C.B., Abbate L.A., Goetz D., Campeas R., Liebowitz M.R. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J. Clin. Psychopharmacol. 18(1):1998;10-18.
110. Masand P.S., Gupta S. Selective serotonin reuptake inhibitors: an update. Harv. Rev. Psychiatry. 7:1999;69-84.
111. Mayer L.E., Walsh B.T. The use of selective serotonin reuptake inhibitors in eating disorders. J. Clin. Psychiatry. 59(Suppl. 15):1998;28-34.
112. Mehlman P.T., Higley J.D., Faucher I., Lilly A.A., Taub M., Vickers J., Suomi S.J., Linnoila M. Low CSF 5-HIAA concentrations, severe aggression and impaired impulse control in nonhuman primates. Am. J. Psychiatry. 151:1994;1485-1491.
113. Mendels J. Sertraline. Sadock B.J., Sadock V.A. Comprehensive Textbook of Psychiatry. vol. 2:1995;2073 Lippincott Williams and Wilkins, USA.
114. Meyer J.H., Kapur S., Eisfeld B., Brown G.M., Houle S., Dasilva J., Wilson A.A., Rafi-Tari S., Mayberg H.S., Kennedy S.H. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F] setoperone PET imaging study. Am. J. Psychiatry. 158(1):2001;78-85.
115. Michelson D., Amsterdam J.D., Quitkin F.M., Reimherr F., Rosenbaum J.F., Zajecka J., Sundell K.L., Kim Y., Beasley C.M. Jr. Changes in weight during one year trial of fluoxetine. Am. J. Psychiatry. 156:1999;1170-1176.
116. Mitchell J.E., Peterson C.B., Myers T., Wonderlich S. Combining pharmacotherapy and psychotherapy in the treatment of patients with eating disorders. Psychiatr. Clin. North Am. 24(2):2001;315-323.
117. Montgomery S.A., McIntyre A., Osterheider M., Sarteschi P., Zitrel W., Zohar Z. A double-blind placebo-controlled study of fluoxetine in patients with DSM-IIIR obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur. Neuropsychopharmacol. 3:1993;143-152.
118. Montgomery S.A., Henry J., McDonald G., Dinan T., Ladder M., Hindmarch I., Clare A., Nutt D. Selective serotonin reuptake inhibitors. A meta-analysis of discontinuation rates. Int. J. Clin. Psychopharmacol. 9:1994;47-53.
119. Montgomery S.A., Dunner D.L., Dunbar G.C. Reduction of suicidal thoughts with paroxetine in comparison with reference to antidepressants and placebo. Eur. Neuropsychopharmacol. 5(1):1995;5-13.
120. Moore P., Landolt H.P., Seifritz E., Clark C., Bhatti T., Kelsoe J., Rapaport M., Gillin J.C. Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology. 23(6):2000;601-622.
121. Mort J.R. Selective serotonin reuptake inhibitors (SSRIs) and falls in the elderly depressed patient. S. D. J. Med. 52(6):1999;201-202.
122. Murdoch D., McTavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive compulsive disorder. Drugs. 44:1992;604-624.
123. Murphy T.K., Bengtson M.A., Tan J.Y., Carbonell E., Levin G.M. Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review. Int. Clin. Psychopharmacol. 15(Suppl. 2):2000;S47-S63.
124. Newman J., Nierenberg A.A. SSRIs in depression: distinctive actions? Stanford S.C. Selective Serotonin Reuptake Inhibitors (SSRIs). Past, Present and Future. 1999;27-46 RG Landes, Austin, TX, USA.
125. Nirenberg A.A. The study of severe depression; is there an efficacy gap between SSRIs and TCAs antidepressant generations? J. Clin. Psychiatry. 55:1994;55-59. (Suppl.).
126. Olesen O.V., Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology. 59(6):1999;298-309.
127. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283:1997;1305-1322.
128. Pande A.C., Birkett M., Fechner-Bates S., Haskett R.F., Greden J.F. Fluoxetine versus phenelzine in atypical depression. Biol. Psychiatry. 40(10):1996;1017-1020.
129. Patterson W.M. Fluoxetine induced sexual dysfunction. J. Clin. Psychiatry. 54:1993;71.
130. Penava S.J., Otto M.W., Pollack M.H., Rosenbaum J.F. Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Depress. Anxiety. 4(5):1996-1997;240-242.
131. Peretti S., Judge R., Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants versus selective serotonin reuptake inhibitors. Acta. Psychiatr. Scand., Suppl. 403:2000;17-25.
132. Perry P.J. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic antidepressants versus selective serotonin reuptake inhibitors. J. Affect. Disord. 39:1996;1-6.
133. Perry P.J., Garvey M.J., Kelly M.W., Cook B.L., Dunner F.J., Winokurg G. A comparative trial of fluoxetine versus trazodone on outpatients with major depression. J. Clin. Psychiatry. 50:1989;290-294.
134. Pigott T.A., Seay S.M. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J. Clin. Psychiatry. 60(2):1999;101-106.
135. Pollock B.G. Citalopram: a comprehensive review. Expert Opin. Pharmacother. 2(4):2001;681-698.
136. Preskorn S.H. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J. Clin. Psychiatry. 54:1993;14-34. (Suppl.).
137. Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int. Clin. Psychopharmacol. 9(Suppl. 3):1994;13-19.
138. Preskorn S.H. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline and venlafaxine. J. Clin. Psychiatry. 56(Suppl. 6):1995;12-21.
139. Preskorn S.H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 32(Suppl. 1):1997;1-21.
140. Preskorn S.H., Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J. Clin. Psychiatry. 53(Suppl. 1):1992;5-18.
141. Preskorn S.H., Fast G.A. Therapeutic drug monitoring for antidepressants: efficacy, safety and cost effectiveness. J. Clin. Psychiatry. 52:1991;23-33. (Suppl.).
142. Preskorn S.H., Lane R.M. Sertraline 50 mgs daily: the optimal dose in the treatment of depression. Int. J. Clin. Psychopharmacol. 10:1995;129-141.
143. Price J.S., Waller P.C., Wood S.M., MacKey A.V. A comparison of postmarketing safety of four selective serotonin reuptake inhibitors including the investigation of symptoms occurring on withdrawal. Br. J. Clin. Pharmacol. 42:1996;757-763.
144. Rapeport W.G., Muirhead D.C., Williams S.A., Cross M., Wesnes K. Absence of effects of sertraline on pharmacokinetics and pharmacodynamics of phenytoin. J. Clin. Psychiatry. 57(Suppl. 1):1996;24-28.
145. Rasmussen B.B., Brosen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther. Drug Monit. 22(2):2000;143-154.
146. Richelson E. Pharmacology of antidepressants characteristics of the ideal antidepressant drug. Mayo Clin. Proc. 69:1994;1069-1081.
147. Rochat B., Amey M., Gillet M., Meyer U.A., Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics. 7(1):1997;1-10.
148. Ronfeld R.A., Tremaine L.H., Wilner K.D. Pharmacokinetics of sertraline and its N-methyl metabolite in elderly and young male and female volunteers. Clin. Pharmacokinet. 32(1):1997;22-30.
149. Roth B.L. Multiple serotonin receptors: clinical and experimental aspects. Ann. Clin. Psychiatry. 6(2):1994;67-78.
150. Rothbaum B., Farfel G. Two multicenter trials evaluating sertraline and placebo for the treatment of PTSD. Presented at the annual meeting of Am. Psychiatric Association (APA) in Washington, DC:1999.
151. Rudorfer M.V., Potter W.Z. The role of metabolites of antidepressants in the treatment of depression. CNS Drugs. 7:1997;273-312.
152. Schmider J., Greenblatt D.J., von Moltke L.L., Karsov D., Shader R.I. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br. J. Clin. Pharmacol. 44(5):1997;495-498.
153. Shalev A.V. Posttraumatic stress disorder: diagnosis, history and life courses. Nutt D., Davidson J., Zohar J. Posttraumatic Stress Disorder, Management and Treatment. 2000;1-2 Martin Dunitz, London, UK.
154. Silver H., Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J. Clin. Psychopharmacol. 18(3):1998;208-211.
155. Sindrup S.H., Brosen K., Hansen M.G., Aayes-Jorgensen T., Overo K.F., Gram L.F. Pharmacokinetics of citalopram in relation to the sparteine and mephetoin oxidation polymorphism. Ther. Drug Monit. 15:1993;11-17.
156. Sjoerdsma T., Palfregman A. History of serotonin. Ann. NY Acad. Sci. 600:1990;2-9.
157. Smith G., Stubbins M.J., Harries L.W., Wolf C.R. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 28(12):1998;1129-1165.
158. Solai L.K., Mulsant B.H., Pollock B.G. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging. 18(5):2001;355-368.
159. Song F., Freemantle N., Sheldon T.A., Watson P., Long A., Mason J. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br. Med. J. 306(6879):1993;683-687.
160. Spigset O., Carleborg L., Hedenmalm K., Dahlqvist R. Effects of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin. Pharmacol. Ther. 58:1995;399-403.
161. Spigset O., Granberg K., Hagg S., Norstrom A., Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur. J. Clin. Pharmacol. 52(2):1997;129-133.
162. Spigset O., Granberg K., Hagg S., Soderstrom E., Carleborg I., Dahlqvist R. Non-linear fluvoxamine disposition and relation to some CYP activities. Eur. J. Clin. Pharmacol. 52:1997;A172. (Suppl.).
163. Spigset O., Granberg K., Hagg S., Soderstrom E., Dahlqvist R. Non-linear fluvoxamine disposition. Br. J. Clin. Pharmacol. 45(3):1998;257-263.
164. Spina E., Avanozo A., Facciola G., Fabrazzo M., Monteleone P., Maj M., Perucca E., Caputi A.P. Effect of fluoxetine on plasma concentration of clozapine and its major metabolites in patients with schizophrenia. Int. Clin. Psychopharmacol. 13:1998;141-145.
165. Stahl S.M. Serotonin neuroscience discoveries usher in a new era of novel drug therapies for psychiatry. Psychopharmacol. Bull. 28(1):1992;3-9.
166. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 51(3):1998;215-235.
167. Stanford S.C. Prozac: panacea or puzzle? Trends Pharmacol. Sci. 17:1996;150-174.
168. Steiner M., Steinberg S., Stewart D., Carted D., Berger C., Reid R. Fluoxetine in the treatment of premenstrual dysphoria. N. Engl. J. Med. 332:1995;1529-1534.
169. Sternbach H. The serotonin syndrome. Am. J. Psychiatry. 148:1991;705-713.
170. Stewart D.E. Are there special considerations in the prescription of serotonin reuptake inhibitors for women? Can. J. Psychiatry. 43(9):1998;900-904.
171. Stock A.J., Kofoed L. Therapeutic interchange of fluoxetine and sertraline: experience in the clinical settings. Am. J. Hosp. Pharm. 51(18):1994;2279-2281.
172. Strober M., Freeman R., Deantonio M., Lampert C., Diamond J. Does adjunctive fluoxetine influence the post-hospital course of restrictive-type anorexia nervosa? A 24-month prospective, longitudinal follow-up and comparison with historical controls. Psychopharmacol. Bull. 33(3):1997;425-431.
173. Sussman N., Stahl S. Update in the pharmacotherapy of depression. Am. J. Med. 101(6A):1996;30S.
174. Szegedi A., Wiesner J., Hiemke C. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J. Clin. Psychopharmacol. 15(2):1995;141-143.
175. Teicher M.H., Glod C., Cole J.O. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am. J. Psychiatry. 147:1990;207-210.
176. Tork I. Anatomy of the serotonergic system. Ann. NY Acad. Sci. 600:1990;9-34.
177. Ueda N., Yoshimura R., Shinkai K., Terao T., Nakamura J. Characteristics of fluvoxamine-induced nausea. Psychiatry Res. 104(3):2001;259-264.
178. Van Amerigen M., Mancini C., Oakman J.M. Selective serotonin reuptake inhibitors in the treatment of social phobia: the emerging gold standard. CNS Drugs. 11:1999;307-315.
179. van der Kolk B.A., Dreyfuss D., Michaels M., Shera D., Berkowitz R., Fisler R., Saxe G. Fluoxetine in posttraumatic stress disorder. J. Clin. Psychiatry. 55(12):1994;517-522.
180. Van der Linden G.J., Stein D.J., van Balkom A.J. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int. Clin. Psychopharmacol. 15(Suppl. 2):2000;S15-S23.
181. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 24(3):1993;203-220.
182. Van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin. Pharmacokinet. 29(Suppl. 1):1995;1-9.
183. van Vliet I.M., den Boer J.A., Westenberg H.G. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berlin). 115(1-2):1994;128-134.
184. von Moltke L.L., Greenblatt D.J., Duan S.X., Schmider J., Kudchadker L., Fogelman S.M., Harmatz J.S., Shader R.I. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes. SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology (Berlin). 128(4):1996;398-407.
185. von Moltke L.L., Greenblatt D.J., Duan S.X., Schmider J., Wright C.E., Harmatz J.S., Shader R.L. Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology (Berlin). 132:1997;402-407.
186. Vythilingum B., Cartwright C., Hollander E. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. 15(Suppl. 2):2000;S7-S13.
187. Wagstaff A.J., Cheer S.M., Matheson A.J., Ormrod D., Goa K.L. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. 62(4):2002;655-703.
188. Walker P.W., Cole J.O., Gardener E.A., Hughes A.R., Johnston A., Batey R.S., Lineberry C.G. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J. Clin. Psychiatry. 54:1993;459-465.
189. Walczak D.D., Apter J.T., Halikas J.A., Borison R.L., Carman J.S., Post G.L., Patrick R., Cohn J.B., Cunningham L.A., Rittberg B., Preskorn S.H., Kang J.S., Wilcox C.S. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann. Clin. Psychiatry. 8(3):1996;139-151.
190. Wheatley D.P., van Moffaert M., Timmerman L., Kremer C.M. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J. Clin. Psychiatry. 59(6):1998;306-312.
191. Wikander I., Sundblad C., Andersch B. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phase more effective than continuous medication throughout the menstrual cycle? J. Clin. Psychopharmacol. 18:1998;390-398.
192. Williams R., Edwards R.A., Newburn G.M., Mullen R., Menkes D.B., Segkar C. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. Int. Clin. Psychopharmacol. 7:1993;155-158.
193. Wong D.T., Bymaster F.P., Engleman E.A. Prozac (fluoxetine, Lilly (1995)), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 57(5):1995;411-441.
194. Workman E.A., Short D.D. Atypical antidepressant versus imipramine in the treatment of major depression: a meta-analysis. J. Clin. Psychiatry. 54:1993;5-12.
195. Xu Z.H., Xie H.G., Zhou H.H. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br. J. Clin. Pharmacol. 42(4):1996;518-521.
196. Ziervogel C.F. Selective serotonin reuptake inhibitors for children and adolescents. Eur. Child Adolesc. Psychiatry. 9(Suppl. 1):2000;I20-I26.
197. Zohar J., Westenberg H.G. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr. Scand., Suppl. 403:2000;39-49.